Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
4.855
+0.045 (0.94%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Company Description
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Ardelyx, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Jun 19, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 395 |
| CEO | Michael Raab |
Contact Details
Address: 400 Fifth Avenue, Suite 210 Waltham, Massachusetts 02451 United States | |
| Phone | 510 745 1700 |
| Website | ardelyx.com |
Stock Details
| Ticker Symbol | ARDX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001437402 |
| CUSIP Number | 039697107 |
| ISIN Number | US0396971071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael G. Raab | President, Chief Executive Officer and Director |
| Elizabeth A. Grammer Esq. | Chief Legal and Administrative Officer and Secretary |
| Dr. Laura A. Williams M.D., M.P.H. | Chief Medical Officer |
| Justin A. Renz CPA, MBA | Chief Financial and Operations Officer |
| Joseph Reilly | Senior Vice President of Finance and Principal Accounting Officer |
| Caitlin Lowie | Vice President of Corporate Communications and Investor Relations |
| Mike Kelliher | Executive Vice President of Corporate Development and Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2025 | 144 | Filing |
| Feb 20, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | 144 | Filing |
| Feb 5, 2025 | SCHEDULE 13G | Filing |
| Jan 16, 2025 | 144 | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 7, 2025 | 144 | Filing |
| Dec 10, 2024 | 144 | Filing |